Like most organizations around the world, Lilly has been closely monitoring the COVID-19 pandemic and its global impact. We are working in line with Government guidance in the UK, and our first priority is to meet our responsibility to protect the health of our people, our customers and our communities.
Lilly does not anticipate shortages for any of our products, including all forms of insulin. Since the initial outbreak, Lilly has been closely monitoring our supply chain for potential impact to the supply of our medicines around the world. Globally, our manufacturing network is fully operational and as the global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicine.
Information on what Lilly is doing globally to make sure our employees and their families are safe, and to ensure people can access Lilly medicines, is available from our corporate website at Lilly.com
Lilly’s top priority is to ensure patients in the UK and in the EU can continue to access the medicines they rely on.
We have undertaken comprehensive analysis of the risks leaving the European Union could pose across our business and, critically, to our ability to supply medicines in the UK. Lilly has worked with Government, the NHS and the broader health system through this process, providing expertise and data to support national contingency planning and cooperating with the Department of Health and Social Care’s stockpiling strategy.
We recognise that patients, pharmacists, and doctors, are particularly concerned about the future supply of medicines in a “no-deal” Brexit scenario. Lilly’s own Brexit investment has been significant. In most cases our planning, including our own medicines stockpiling, exceeds government guidance.
While Lilly has done everything in its power to prepare for Brexit, circumstances outside of our responsibility could still disrupt medicines supply. This includes delays at ports of entry, freight capacity on sea and air routes, volatility in demand for medicines due to stockpiling outside of our supply chain, and unpredictable fluctuations in parallel import and export.
Patients should not be disadvantaged by the UK leaving the EU and our focus will remain firmly on ensuring we can supply Lilly medicines to the patients that need them.